AstraZeneca Pharma India gets CDSCO nod to import, distribute lung cancer drug Osimertinib Ruchika Sharma7 April 2025 12:30 PM ISTBangalore: AstraZeneca Pharma India Limited has received permission from the Central Drugs Standard Control Organization...
AstraZeneca Tagrisso approved in EU for patients with unresectable EGFR-mutated lung cancer Ruchika Sharma27 Dec 2024 11:30 AM ISTCambridge: AstraZeneca's Tagrisso (osimertinib) has been approved in the European Union (EU) for the treatment of adult patients with...
Delhi HC Upholds AstraZeneca's Tagrisso Patent, Imposes Rs 7L Fine on 'Habitual Infringer' for Knockoff Production Farhat Nasim2 Dec 2024 4:48 PM ISTNew Delhi: In a major relief to AstraZeneca, the Delhi High Court has granted summary judgment, confirming that Westcoast Pharmaceutical Works Ltd....
AstraZeneca Tagrisso recommended for approval in EU by CHMP for patients with unresectable EGFR mutated lung cancer Ruchika Sharma19 Nov 2024 12:15 PM ISTCambridge: AstraZeneca's Tagrisso (osimertinib) has been recommended for approval in the European Union (EU) for the treatment of adult patients...
AstraZeneca gets USD 107 million Pfizer verdict overturned in US cancer drug patent fight Ruchika Sharma19 Aug 2024 4:45 PM ISTCambridge: AstraZeneca has convinced a Delaware federal judge to throw out a jury's decision that the company owes USD 107.5 million for...
AstraZeneca Tagrisso plus chemotherapy approved in EU for EGFR-mutated advanced lung cancer Ruchika Sharma8 July 2024 11:30 AM ISTCambridge: AstraZeneca has announced that Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy has been...
AstraZeneca Tagrisso gets USFDA priority review for unresectable, Stage III EGFR-mutated lung cancer Ruchika Sharma11 Jun 2024 11:39 AM ISTAstraZeneca's supplemental New Drug Application (sNDA) for TAGRISSO (osimertinib) has been accepted and granted Priority Review in the US for the...
AstraZeneca Tagrisso, chemotherapy recommended for approval in EU by CHMP for EGFR-mutated advanced lung cancer Ruchika Sharma5 Jun 2024 2:00 PM ISTCambridge: AstraZeneca's Tagrisso (osimertinib) with the addition of pemetrexed and platinum-based chemotherapy has been recommended for...
AstraZeneca Tagrisso with chemotherapy approved in US for EGFR-mutated advanced lung cancer Ruchika Sharma17 Feb 2024 12:00 PM ISTTagrisso (osimertinib) is a third-generation, irreversible EGFR-TKI with proven clinical activity in NSCLC, including against CNS metastases.
AstraZeneca gets USFDA priority review for Tagrisso plus chemotherapy for EGFR-mutated advanced lung cancer Ruchika Sharma17 Oct 2023 2:24 PM ISTCambridge: AstraZeneca’s supplemental New Drug Application (sNDA) for Tagrisso (osimertinib) in combination with chemotherapy has been accepted and...
AstraZeneca declares positive results from trial of Tagrisso plus chemotherapy to treat EGFR-mutated advanced lung cancer Ruchika Sharma12 Sept 2023 1:30 PM ISTCambridge: AstraZeneca has announced positive results from FLAURA2 phase III trial of Tagrisso (osimertinib) in combination with chemotherapy for...
GSK, Sanofi, Pfizer and other drugmakers plan to raise prices on at least 350 drugs in US in January Ruchika Sharma31 Dec 2022 1:15 PM ISTTo date, Pfizer announced the most increases, with prices rising on 89 unique drug brands, and an additional increase on 10 drug brands at its Hospira...
